Eupraxia Pharmaceuticals Inc. (EPRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Victoria, BC, Canada. The current CEO is James A. Helliwell.
EPRX has IPO date of 2024-04-05, 33 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $241.73M.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
